Compare Natera Inc. Common Stock (NTRA) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs IAC/Interactivecorp — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while IAC/Interactivecorp trades at $40.57 (market cap $3.04B). The key difference: Natera Inc. Common Stock is far larger — about 18.8× IAC/Interactivecorp's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and IAC/Interactivecorp for 80 Days on average.
| NTRA | PPLI | |
|---|---|---|
Market Cap | $57.03B | $3.04B |
Volume | 1,131,157 | 686,384 |
Sector | Health | Media |
52-Week High | $425.64 | $47.62 |
52-Week Low | $179.42 | $31.52 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $56.18B | $3.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PPLI trades at $40.56, down 0.73% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $104.03M in 2025 despite strong gross margins of 66.35%, with valuation metrics appearing attractive at P/E of 6.91 and P/B of 0.6. Recent MGM acquisition speculation has driven significant volatility, with shares surging 11.3% on takeover rumors according to Zacks Investment Research on September 28, 2026.
The outlook remains speculative with 71% analyst buy ratings supporting potential upside from strategic developments, though fundamental weakness in recent earnings and negative cash flow trends present significant risks. Investors face binary outcomes dependent on MGM deal progression versus underlying business challenges in the media sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
